Apifixa Subsidiary Of Orthopediatrics Corp Specializes In Innovative Scoliosis Correction Technologies For Pediatric Patientsbased In Israelthe Company Focuses On Treating Adolescent Idiopathic Scoliosisaiswith Its Advanced Apifixamid C Systemthis System Offers A Less Invasive Alternative To Spinal Fusionutilizing A Unilateral Design That Allows For Growth And Preserves Spinal Motion The Apifixamid C System Features A Self Adjusting Rod Mechanism And Is Indicated For Flexible Ais Curves Measuring 35Ae 60 Degreesit Has Been Successfully Used In Over 800 Cases Globally Since Its Introduction In 2012Apifix Is Committed To Expanding Treatment Options For Ais Patientsproviding Solutions That Enhance Quality Of Life While Minimizing The Need For Permanent Surgical Interventionsthe Company Operates Internationallywith Approvals In The U S Canadaeuropeand Other Regionssupported By A Distribution Network That Spans 44 Countries
